Leiden, the Netherlands, 29 April 2013 / B3C newswire / - Batavia Bioservices BV and UvA Holding BV announced today that they have successfully concluded an agreement granting Batavia Bioservices the exclusive rights to STEP™ technology developed by scientists at CellaGenics BV, an UvA Holding BV company.
Under the agreement, Batavia Bioservices has been granted the exclusive license to the STEP™ technology, a revolutionary, plasmid-based system that significantly reduces the time required to develop recombinant protein-producing mammalian cell lines while increasing protein production more than 10-fold.
Menzo Havenga (CEO Batavia Bioservices) commented: “We are very pleased that UvA Holding has selected Batavia Bioservices as its marketing partner for STEP™ technology since we firmly believe that this technology will significantly reduce manufacturing costs."
Chris Yallop (COO Batavia Bioservices) added: “STEP™ technology also allows the development of so-called rare diseases biopharmaceutical products, which have always been considered too expensive to develop."
Piet Scholten (Director UvA Holding BV) concluded: “With their in-depth know how in biopharm manufacturing, vast network, and presence in both Europe and USA, Batavia Bioservices provided the ideal landing platform for marketing our technology and we look forward to a fruitful relationship!”
Financial details of the exclusive license agreement were not disclosed.
About Batavia Bioservices BV
Batavia Bioservices is a biopharmaceutical process & product development services company, dedicated to add value to its customers by providing high quality biopharmaceuticals for proof-of—concept studies as well as pre-clinical and clinical materials. The company, headquartered in Leiden the Netherlands has in-depth know how regarding manufacturing of recombinant proteins, antibodies and vaccines.
About UvA Holding BV
UvA Holding is a private company and a 100% subsidiary of University of Amsterdam. The company develops, implements and manages market-oriented activities which are non-core but at the same time directly related to the university.
Contact
Menzo Havenga
CEO Batavia Bioservices BV
+31 (0) 888 66 96 42
This email address is being protected from spambots. You need JavaScript enabled to view it.This email address is being protected from spambots. You need JavaScript enabled to view it.
or
Chris Yallop
COO Batavia Bioservices BV
+31 (0) 888 66 96 76
This email address is being protected from spambots. You need JavaScript enabled to view it.This email address is being protected from spambots. You need JavaScript enabled to view it.